{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:10:01Z","timestamp":1792815001123,"version":"4.5.0"},"reference-count":273,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The treatment paradigm for lymphoma, a highly heterogeneous group of hematologic malignancies, has been revolutionized by the development of therapies targeting oncogenic signaling pathways. This shift from conventional chemotherapy to precision medicine is driven by a deep molecular understanding of the pathways that govern lymphoma cell survival and proliferation. This review comprehensively surveys the landscape of these targeted therapies, from fundamental molecular mechanisms to clinical breakthroughs. We first dissect the molecular architecture of key oncogenic drivers, covering foundational survival networks such as the B-cell receptor, phosphatidylinositol 3-kinase \/protein kinase B\/mammalian target of rapamycin, Janus kinase\/signal transducer and activator of transcription, and B-cell lymphoma 2 apoptosis pathways; critical regulatory processes like nuclear export controlled by exportin 1 and epigenetic patterns. For each therapeutic class, we discuss the clinical development of specific inhibitors and the challenge of acquired resistance. Furthermore, we examine emerging concepts in lymphoma, including the context-dependent role of the cyclic guanosine monophosphate\u2013adenosine monophosphate synthase-stimulator of interferon genes pathway, to provide a comprehensive overview of the current therapeutic landscape. A central theme of this review is the integration of these targeted agents into clinical practice. We discuss how the successful targeting of oncogenic signaling pathways has enabled the development of effective chemotherapy-free regimens, which offer durable responses with reduced toxicity and improved quality of life. Although initially transformative for patients with indolent lymphomas or those unfit for intensive chemotherapy, this paradigm is now extending to aggressive lymphomas as well. Another pivotal advance is the use of molecular subtyping and predictive biomarkers to guide treatment. As powerfully demonstrated by recent clinical trials, aligning targeted agents with the specific signaling or epigenetic dependencies of a tumor subtype can significantly enhance the efficacy of standard immunochemotherapy backbones in both B-cell and T-cell lymphomas. Finally, we address the persistent challenges of acquired resistance and discuss future directions, including the development of next-generation agents such as proteolysis-targeting chimeras, the design of rational, synergistic combination strategies, and the leveraging of multiomics and artificial intelligence to decipher complex signaling networks. By continuing to translate molecular insights into clinical practice, the field is steadily moving toward the goal of achieving precision cures for patients with lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004017","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:00:08Z","timestamp":1772010008000},"page":"949-972","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs"],"prefix":"10.1097","volume":"139","author":[{"given":"Shuqi","family":"Wang","sequence":"first","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuran","family":"Qiu","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China"},{"name":"P\u00f4le de Recherches Sino-Fran\u00e7ais en Science du Vivant et G\u00e9nomique, Laboratory of Molecular Pathology, Shanghai 200025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"R1-20260405","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: Myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"R2-20260405","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/ejh.12589","article-title":"The molecular pathogenesis of b-cell non-hodgkin lymphoma","volume":"95","author":"Blombery","year":"2015","journal-title":"Eur J Haematol"},{"key":"R3-20260405","first-page":"351","article-title":"Non-hodgkin\u2019s lymphomas: Current classification and management","volume":"47","author":"Skarin","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"R4-20260405","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrclinonc.2014.137","article-title":"Precision therapy for lymphoma--current state and future directions","volume":"11","author":"Intlekofer","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-20260405","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-b-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"R6-20260405","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and opportunities in the management of diffuse large b-cell lymphoma in older patients","volume":"26","author":"Di","year":"2021","journal-title":"Oncologist"},{"key":"R7-20260405","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral t cell lymphomas: From the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R8-20260405","article-title":"Rate of primary refractory disease in b and t-cell non-hodgkin\u2019s lymphoma: Correlation with long-term survival","volume":"9","author":"Bertolini","year":"2014","journal-title":"PLoS ONE"},{"key":"R9-20260405","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.14694\/EdBook_AM.2014.34.e240","article-title":"Personalizing therapy for older adults with lymphoid malignancies: Options and obstacles","author":"Wildes","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R10-20260405","doi-asserted-by":"crossref","DOI":"10.3892\/or.2023.8621","article-title":"Single\u2011cell multi\u2011omics advances in lymphoma research (review)","volume":"50","author":"Jin","year":"2023","journal-title":"Oncol Rep"},{"key":"R11-20260405","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large b cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"R12-20260405","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large b cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"R13-20260405","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ccell.2025.06.002","article-title":"Large b cell lymphoma microenvironment archetype profiles","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"R14-20260405","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic card11 mutations in human diffuse large b cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"key":"R15-20260405","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccell.2022.01.013","article-title":"All roads lead to targeted diffuse large b-cell lymphoma approaches","volume":"40","author":"Xu","year":"2022","journal-title":"Cancer Cell"},{"key":"R16-20260405","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in x-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"R17-20260405","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.180.2.461","article-title":"Deletion within the src homology domain 3 of bruton\u2019s tyrosine kinase resulting in x-linked agammaglobulinemia (xla)","volume":"180","author":"Zhu","year":"1994","journal-title":"J Exp Med"},{"key":"R18-20260405","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41586-022-05412-7","article-title":"Structural principles of b cell antigen receptor assembly","volume":"612","author":"Dong","year":"2022","journal-title":"Nature"},{"key":"R19-20260405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jgg.2019.12.003","article-title":"Structural and immunogenomic insights into b-cell receptor activation","volume":"47","author":"Feng","year":"2020","journal-title":"J Genet Genomics"},{"key":"R20-20260405","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin Cancer Biol"},{"key":"R21-20260405","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcancer.2016.07.003","article-title":"Malt lymphoma: A paradigm of nf-\u03bab dysregulation","volume":"39","author":"Du","year":"2016","journal-title":"Semin Cancer Biol"},{"key":"R22-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1095257","article-title":"Card11 gain-of-function mutation drives cell-autonomous accumulation of pd-1+ icoshigh activated t cells, t-follicular, t-regulatory and t-follicular regulatory cells","volume":"14","author":"Masle-Farquhar","year":"2023","journal-title":"Front Immunol"},{"key":"R23-20260405","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting b cell receptor signalling in cancer: Preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"R24-20260405","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting btk with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"R25-20260405","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"R26-20260405","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of mcl patients treated with single-agent ibrutinib: Updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"R27-20260405","article-title":"Second-generation inhibitors of bruton tyrosine kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"R28-20260405","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (elevate-tn): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"The Lancet"},{"key":"R29-20260405","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1200\/JCO.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic waldenstr\u00f6m macroglobulinemia: Final analysis from the randomized phase iii aspen study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"R30-20260405","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory mcl: A phase 1\/2, open-label, multicenter, single-arm study","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv"},{"key":"R31-20260405","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: A single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"R32-20260405","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (philemon): A multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"key":"R33-20260405","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"Rosewood: A phase ii randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"key":"R34-20260405","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1182\/blood-2023-178509","article-title":"A prospective multicenter phase ii study of orelabrutinib-lenalidomide-rituximab (olr) in patients with untreated mantle cell lymphoma (mcl) in china (polaris study): Preliminary analysis on efficacy, safety, mutation spectrum and impact of mutation profiling on treatment responses","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"R35-20260405","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/bloodadvances.2020003423","article-title":"Overcoming resistance to targeted therapies in chronic lymphocytic leukemia","volume":"5","author":"Sk\u00e5nland","year":"2021","journal-title":"Blood Adv"},{"key":"R36-20260405","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of btk, bcl2, and plcg2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R37-20260405","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory b-cell malignancies (bruin): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"R38-20260405","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent bruton\u2019s tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"R39-20260405","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/COC.0000000000001170","article-title":"Bruton tyrosine kinase degraders: Current concepts","volume":"48","author":"Sabakhtarishvili","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"R40-20260405","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3294","article-title":"Strategies for overcoming resistance to bruton\u2019s tyrosine kinase inhibitor zanubrutinib","volume":"42","author":"Dost\u00e1lov\u00e1","year":"2024","journal-title":"Hematol Oncol"},{"key":"R41-20260405","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of btk and malt1 overcomes resistance to btk inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"Journal of Clinical Investigation"},{"key":"R42-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-024-00589-7","article-title":"The cdk9 inhibitor enitociclib overcomes resistance to btk inhibition and car-t therapy in mantle cell lymphoma","volume":"12","author":"Jiang","year":"2024","journal-title":"Biomark Res"},{"key":"R43-20260405","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"key":"R44-20260405","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","article-title":"Xpo1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of i\u03bab","volume":"17","author":"Ming","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R45-20260405","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2643-3230.BCD-21-0063","article-title":"Overcoming acquired epigenetic resistance to btk inhibitors","volume":"2","author":"Shaffer","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"R46-20260405","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/CM9.0000000000003504","article-title":"Efficacy and safety of chimeric antigen receptor t cell therapy combined with zanubrutinib in the treatment of relapsed\/refractory diffuse large b-cell lymphoma","volume":"138","author":"Wang","year":"2025","journal-title":"Chin Med J"},{"key":"R47-20260405","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/bph.12431","article-title":"Cell death and the mitochondria: Therapeutic targeting of the bcl-2 family-driven pathway","volume":"171","author":"Roy","year":"2014","journal-title":"Br J Pharmacol"},{"key":"R48-20260405","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s10495-014-1051-7","article-title":"The bcl-2 family: Structures, interactions and targets for drug discovery","volume":"20","author":"Kvansakul","year":"2014","journal-title":"Apoptosis"},{"key":"R49-20260405","article-title":"The bcl2 family: From apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R50-20260405","article-title":"Cell death pathways: Molecular mechanisms and therapeutic targets for cancer","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"R51-20260405","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41418-017-0010-6","article-title":"Mcl-1 and bcl-xl sequestration of bak confers differential resistance to bh3-only proteins","volume":"25","author":"Hockings","year":"2018","journal-title":"Cell Death Differ"},{"key":"R52-20260405","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41418-024-01273-x","article-title":"Endogenous bax and bak form mosaic rings of variable size and composition on apoptotic mitochondria","volume":"31","author":"Schweighofer","year":"2024","journal-title":"Cell Death Differ"},{"key":"R53-20260405","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/cdd.2008.189","article-title":"Regulation of heat-induced apoptosis by mcl-1 degradation and its inhibition by hsp70","volume":"16","author":"Stankiewicz","year":"2009","journal-title":"Cell Death Differ"},{"key":"R54-20260405","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective bcl-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"R55-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/biom10010128","article-title":"The bcl-2 family: Ancient origins, conserved structures, and divergent mechanisms","volume":"10","author":"Banjara","year":"2020","journal-title":"Biomolecules"},{"key":"R56-20260405","article-title":"Bcl-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"R57-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040938","article-title":"Bcl-2 proteins in pathogenesis and therapy of b-cell non-hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R58-20260405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1525-1578(10)60693-9","article-title":"Microarray analysis of b-cell lymphoma cell lines with the t(14;18)","volume":"4","author":"Robetorye","year":"2002","journal-title":"J Mol Diagn"},{"key":"R59-20260405","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1097-2765(01)00320-3","article-title":"Bcl-2, bcl-x(l) sequester bh3 domain-only molecules preventing bax- and bak-mediated mitochondrial apoptosis","volume":"8","author":"Cheng","year":"2001","journal-title":"Mol Cell"},{"key":"R60-20260405","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The rise of apoptosis: Targeting apoptosis in hematologic malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"key":"R61-20260405","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","article-title":"Targeting bcl-2 in b-cell lymphomas","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"key":"R62-20260405","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.97","article-title":"Bcl-2 is dispensable for thrombopoiesis and platelet survival","volume":"6","author":"Debrincat","year":"2015","journal-title":"Cell Death Dis"},{"key":"R63-20260405","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1158\/1535-7163.MCT-16-0031","article-title":"Bcl2 inhibitors as anticancer drugs: A plethora of misleading bh3 mimetics","volume":"15","author":"R","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"R64-20260405","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: Mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"R65-20260405","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the murano phase iii study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"key":"R66-20260405","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel bcl-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: First-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R67-20260405","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2023-183071","article-title":"Updated efficacy and safety results of lisaftoclax (apg-2575) in patients (pts) with heavily pretreated chronic lymphocytic leukemia (cll): Pooled analyses of two clinical trials","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"},{"key":"R68-20260405","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus r-chop as first-line treatment for patients with diffuse large b-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"R69-20260405","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-020-01007-9","article-title":"Mcl-1 inhibitors, fast-lane development of a new class of anti-cancer agents","volume":"13","author":"Bolomsky","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R70-20260405","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting bcl-2 in b-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"R71-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to bcl-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"R72-20260405","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2022017341","article-title":"Mechanisms of resistance to venetoclax","volume":"140","author":"Condoluci","year":"2022","journal-title":"Blood"},{"key":"R73-20260405","article-title":"Venetoclax-resistant mv4-11 leukemic cells activate pi3k\/akt pathway for metabolic reprogramming and redox adaptation for survival","volume":"11","author":"Alkhatabi","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"R74-20260405","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","article-title":"Synergistic activity of combined inhibition of anti-apoptotic molecules in b-cell precursor all","volume":"36","author":"Seyfried","year":"2022","journal-title":"Leukemia"},{"key":"R75-20260405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo6891","article-title":"The path to venetoclax resistance is paved with mutations, metabolism, and more","volume":"14","author":"Sullivan","year":"2022","journal-title":"Sci Transl Med"},{"key":"R76-20260405","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.26809","article-title":"Targeting mcl-1 and bcl-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in r\/r non-hodgkin lymphoma: Results from preclinical models and a phase ib study","volume":"98","author":"Lasater","year":"2023","journal-title":"Am J Hematol"},{"key":"R77-20260405","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive b-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R78-20260405","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06878-1","article-title":"Correction to: Mcl-1 and bcl-xl-dependent resistance to the bcl-2 inhibitor abt-199 can be overcome by preventing pi3k\/akt\/mtor activation in lymphoid malignancies","volume":"15","author":"Choudhary","year":"2024","journal-title":"Cell Death Dis"},{"key":"R79-20260405","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/s41375-022-01627-9","article-title":"Tipping the balance: Toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma","volume":"36","author":"Thus","year":"2022","journal-title":"Leukemia"},{"key":"R80-20260405","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus chop (r-chop) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large b-cell lymphoma (dlbcl)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"key":"R81-20260405","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.283245","article-title":"Hypomethylating agent decitabine sensitizes diffuse large b-cell lymphoma to venetoclax","author":"Zhu","year":"2023","journal-title":"Haematologica"},{"key":"R82-20260405","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11912-011-0187-7","article-title":"Targeting the pi3k\/akt\/mtor pathway in non-hodgkin\u2019s lymphoma: Results, biology, and development strategies","volume":"13","author":"Schatz","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"R83-20260405","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3037","article-title":"Pten loss in the continuum of common cancers, rare syndromes and mouse models","volume":"11","author":"Hollander","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"R84-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01827-6","article-title":"Pi3k\/akt\/mtor signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"R85-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00224","article-title":"The phosphoinositide 3-kinase signaling pathway in normal and malignant b cells: Activation mechanisms, regulation and impact on cellular functions","volume":"3","author":"Pauls","year":"2012","journal-title":"Front Immunol"},{"key":"R86-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102886","article-title":"Mechanisms of resistance to mTOR inhibitors","volume":"147","author":"Formisano","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"R87-20260405","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"Pi3k\u03b4-selective and pi3k\u03b1\/\u03b4-combinatorial inhibitors in clinical development for b-cell non-hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"R88-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073464","article-title":"Pi3k inhibitors in cancer: Clinical implications and adverse effects","volume":"22","author":"Mishra","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R89-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061571","article-title":"Pi3k inhibitors for the treatment of chronic lymphocytic leukemia: Current status and future perspectives","volume":"14","author":"Hus","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R90-20260405","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"Dynamo: A phase ii study of duvelisib (ipi-145) in patients with refractory indolent non-hodgkin lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"R91-20260405","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (pi3k) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R92-20260405","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/hematology.2020000119","article-title":"Managing toxicities of phosphatidylinositol-3-kinase (pi3k) inhibitors","volume":"2020","author":"Hanlon","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R93-20260405","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.0034","article-title":"Safety, tolerability, and management of toxic effects of phosphatidylinositol 3-kinase inhibitor treatment in patients with cancer","volume":"5","author":"Esposito","year":"2019","journal-title":"JAMA Oncol"},{"key":"R94-20260405","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.seminoncol.2016.11.011","article-title":"Pi3k signaling pathway in normal b cells and indolent b-cell malignancies","volume":"43","author":"Pongas","year":"2016","journal-title":"Semin Oncol"},{"key":"R95-20260405","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel pi3k\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: An open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"key":"R96-20260405","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a dual pi3k\u03b4\/ck1\u03b5 inhibitor in patients with relapsed or refractory indolent lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J Clin Oncol"},{"key":"R97-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102131","article-title":"Parsaclisib, a pi3k\u03b4 inhibitor, in relapsed and refractory mantle cell lymphoma (citadel-205): A phase 2 study","volume":"62","author":"Zinzani","year":"2023","journal-title":"eClinicalMedicine"},{"key":"R98-20260405","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral pi3k\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: A phase ii, single-arm, open-label clinical trial","volume":"29","author":"Wang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R99-20260405","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.2147\/DDDT.S142406","article-title":"Copanlisib for treatment of b-cell malignancies: The development of a pi3k inhibitor with considerable differences to idelalisib","volume":"12","author":"Krause","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R100-20260405","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11523-021-00802-9","article-title":"Copanlisib for the treatment of malignant lymphoma: Clinical experience and future perspectives","volume":"16","author":"Munoz","year":"2021","journal-title":"Target Oncol"},{"key":"R101-20260405","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/ajh.25711","article-title":"Long-term safety and efficacy of the pi3k inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the chronos-1 study","volume":"95","author":"Dreyling","year":"2020","journal-title":"Am J Hematol"},{"key":"R102-20260405","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase ii study of copanlisib, a pi3k inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"R103-20260405","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1182\/blood-2024-203577","article-title":"Duvelisib in patients with relapsed\/refractory peripheral t-cell lymphoma: Final results from the phase 2 primo trial","volume":"144","author":"Mehta-Shah","year":"2024","journal-title":"Blood"},{"key":"R104-20260405","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mtorc1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed t-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"key":"R105-20260405","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/blood-2015-05-644724","article-title":"Mtor inhibition in t-cell lymphoma: A path(way) forward","volume":"126","author":"Moskowitz","year":"2015","journal-title":"Blood"},{"key":"R106-20260405","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/annonc\/mdv624","article-title":"A phase ii study of everolimus (rad001), an mtor inhibitor plus chop for newly diagnosed peripheral t-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"R107-20260405","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1158\/1078-0432.CCR-20-1215","article-title":"Safety and efficacy of vorinostat plus sirolimus or everolimus in patients with relapsed refractory hodgkin lymphoma","volume":"26","author":"Janku","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R108-20260405","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41375-024-02401-9","article-title":"Potent combination benefit of the akt inhibitor capivasertib and the bcl-2 inhibitor venetoclax in diffuse large b cell lymphoma","volume":"38","author":"Willis","year":"2024","journal-title":"Leukemia"},{"key":"R109-20260405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the pi3k\/akt\/mtor signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R110-20260405","first-page":"1","article-title":"Pi3k inhibitors in nhl and cll: An unfulfilled promise","volume":"13","author":"Bou Zeid","year":"2023","journal-title":"Blood Lymphat Cancer"},{"key":"R111-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-6057-7","article-title":"Interleukin-6 mediates resistance to pi3k-pathway\u2013targeted therapy in lymphoma","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"key":"R112-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"Protacs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"Eur J Med Chem"},{"key":"R113-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-024-00568-6","article-title":"Vertical targeting of the pi3k\/akt pathway at multiple points is synergistic and effective for non-hodgkin lymphoma","volume":"13","author":"Kupcova","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"R114-20260405","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2021.10.010","article-title":"Ezh2 inhibition confers pik3ca-driven lung tumors enhanced sensitivity to pi3k inhibition","volume":"524","author":"Chen","year":"2022","journal-title":"Cancer Lett"},{"key":"R115-20260405","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","article-title":"Duvelisib plus romidepsin in relapsed\/refractory t cell lymphomas: A phase 1b\/2a trial","volume":"30","author":"Horwitz","year":"2024","journal-title":"Nat Med"},{"key":"R116-20260405","article-title":"Ezh2 abnormalities in lymphoid malignancies: Underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"R117-20260405","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large b cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"key":"R118-20260405","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at ezh2 y641 act dominantly through a mechanism of selectively altered prc2 catalytic activity, to increase h3k27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"key":"R119-20260405","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/j.seminhematol.2015.01.003","article-title":"The epigenetic basis of diffuse large b-cell lymphoma","volume":"52","author":"Jiang","year":"2015","journal-title":"Semin Hematol"},{"key":"R120-20260405","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ccell.2020.10.008","article-title":"Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines","volume":"38","author":"Zhao","year":"2020","journal-title":"Cancer Cell"},{"key":"R121-20260405","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an ezh2 inhibitor, in relapsed or refractory b-cell non-hodgkin lymphoma and advanced solid tumours: A first-in-human, open-label, phase 1 study","volume":"19","author":"Italiano","year":"2018","journal-title":"Lancet Oncol"},{"key":"R122-20260405","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"R123-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103157","article-title":"Efficacy of tazemetostat in combination with r-chop in elderly patients newly diagnosed with diffuse large b cell lymphoma: Results of the epirchop phase ii study of the lysa","volume":"82","author":"Sarkozy","year":"2025","journal-title":"eClinicalMedicine"},{"key":"R124-20260405","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5582\/ddt.2022.01085","article-title":"Valemetostat: First approval as a dual inhibitor of ezh1\/2 to treat adult t-cell leukemia\/lymphoma","volume":"16","author":"Dou","year":"2022","journal-title":"Drug Discov Ther"},{"key":"R125-20260405","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive ezh1 and ezh2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"key":"R126-20260405","doi-asserted-by":"crossref","first-page":"530","DOI":"10.20892\/j.issn.2095-3941.2018.0380","article-title":"Targeting ezh1\/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57cdkn1c and tp53inp1 in mantle cell lymphoma","volume":"16","author":"Li","year":"2019","journal-title":"Cancer Biol Med"},{"key":"R127-20260405","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult t-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"key":"R128-20260405","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral t-cell lymphoma (valentine-ptcl01): A multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol"},{"key":"R129-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1578665","article-title":"Dual targeting of ezh2 and pd-l1 in burkitt\u2019s lymphoma enhances immune activation and induces apoptotic pathway","volume":"16","author":"Jeong","year":"2025","journal-title":"Front Immunol"},{"key":"R130-20260405","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0034-1386763","article-title":"Abnormalities of the DNA methylation mark and its machinery: An emerging cause of neurologic dysfunction","volume":"34","author":"Weissman","year":"2014","journal-title":"Semin Neurol"},{"key":"R131-20260405","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large b-cell lymphoma","volume":"3","author":"Clozel","year":"2013","journal-title":"Cancer Discov"},{"key":"R132-20260405","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jgg.2020.04.006","article-title":"DNA methyltransferases in hematological malignancies","volume":"47","author":"Hoang","year":"2020","journal-title":"J Genet Genomics"},{"key":"R133-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1199108","article-title":"Biological insights into the role of tet2 in t cell lymphomas","volume":"13","author":"Carty","year":"2023","journal-title":"Front Oncol"},{"key":"R134-20260405","article-title":"Methylation alterations and advance of treatment in lymphoma","volume":"26","author":"Zhao","year":"2021","journal-title":"Front Biosci (Landmark Ed)"},{"key":"R135-20260405","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-020-00761-9","article-title":"Hypomethylating agents in lymphoma","volume":"21","author":"Cogan","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"R136-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010633","article-title":"Targeting DNA methylation in leukemia, myelodysplastic syndrome, and lymphoma: A potential diagnostic, prognostic, and therapeutic tool","volume":"24","author":"Kalinkova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R137-20260405","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/annonc\/mdf314","article-title":"DNA methyltransferase inhibitors\u2014state of the art","volume":"13","author":"Goffin","year":"2002","journal-title":"Ann Oncol"},{"key":"R138-20260405","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The idh2 r172k mutation associated with angioimmunoblastic t-cell lymphoma produces 2hg in t cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R139-20260405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"R140-20260405","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","article-title":"Idh2 and tet2 mutations synergize to modulate t follicular helper cell functional interaction with the aitl microenvironment","volume":"41","author":"Leca","year":"2023","journal-title":"Cancer Cell"},{"key":"R141-20260405","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1093\/nar\/gkq187","article-title":"Targeting of 5-aza-2\u2032-deoxycytidine residues by chromatin-associated dnmt1 induces proteasomal degradation of the free enzyme","volume":"38","author":"Patel","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"R142-20260405","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/s41375-022-01571-8","article-title":"Integrated clinical and genomic evaluation of guadecitabine (sgi-110) in peripheral t-cell lymphoma","volume":"36","author":"Wong","year":"2022","journal-title":"Leukemia"},{"key":"R143-20260405","article-title":"Multicenter phase 2 study of oral azacitidine (cc-486) plus chop as initial treatment for peripheral t-cell lymphoma","author":"Ruan","year":"2023","journal-title":"Blood"},{"key":"R144-20260405","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with ptcl: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"R145-20260405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase ii study of anti-pd-1 camrelizumab plus decitabine in relapsed\/refractory hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R146-20260405","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti\u2013pd-1 antibody camrelizumab in relapsed\/refractory classical hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"R147-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1410638","article-title":"A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed\/refractory aitl","volume":"15","author":"Ricard","year":"2024","journal-title":"Front Immunol"},{"key":"R148-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of hdac inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci"},{"key":"R149-20260405","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (fr901228), in the treatment of peripheral and cutaneous t-cell lymphoma: A case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"R150-20260405","first-page":"282","article-title":"Management of t-cell malignancies: Bench-to-bedside targeting of epigenetic biology","volume":"75","author":"Sabzevari","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"R151-20260405","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/CM9.0000000000003214","article-title":"Chidamide triggers pyroptosis in t-cell lymphoblastic lymphoma\/leukemia via the foxo1\/gsdme axis","volume":"138","author":"Li","year":"2025","journal-title":"Chin Med J"},{"key":"R152-20260405","first-page":"859","article-title":"The discovery and development of romidepsin for the treatment of t-cell lymphoma","volume":"12","author":"Smolewski","year":"2017","journal-title":"Expert Opin Drug Discov"},{"key":"R153-20260405","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cam4.939","article-title":"Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral t-cell lymphoma","volume":"6","author":"Foss","year":"2016","journal-title":"Cancer Med"},{"key":"R154-20260405","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral t cell lymphoma: Prolonged stable disease provides clinical benefits for patients in the pivotal trial","volume":"9","author":"Foss","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R155-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115212","article-title":"Anticancer clinical efficiency and stochastic mechanisms of belinostat","volume":"165","author":"El Omari","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R156-20260405","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral t-cell lymphoma: Results of the pivotal phase ii belief (cln-19) study","volume":"33","author":"O\u2019Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"R157-20260405","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/2040620715592567","article-title":"Belinostat in patients with refractory or relapsed peripheral t-cell lymphoma: A perspective review","volume":"6","author":"Sawas","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"R158-20260405","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of chidamide for peripheral t-cell lymphoma, the first orphan drug approved in china","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"R159-20260405","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase ii study of chidamide in relapsed or refractory peripheral t-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"R160-20260405","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70919","article-title":"Chidamide, a histone deacetylase inhibitor, combined with r-gemox in relapsed\/refractory diffuse large b-cell lymphoma (trust): A multicenter, single-arm, phase 2 trial","volume":"14","author":"Zou","year":"2025","journal-title":"Cancer Med"},{"key":"R161-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104420","article-title":"Histone deacetylases inhibitor chidamide synergizes with humanized pd1 antibody to enhance t-cell chemokine expression and augment ifn-\u03b3 response in nk-t cell lymphoma","volume":"87","author":"Wen","year":"2023","journal-title":"eBioMedicine"},{"key":"R162-20260405","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.13566","article-title":"The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of t-cell lymphoma","volume":"171","author":"Marchi","year":"2015","journal-title":"Br J Haematol"},{"key":"R163-20260405","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1182\/blood.2019000381","article-title":"Melk mediates the stability of ezh2 through site-specific phosphorylation in extranodal natural killer\/t-cell lymphoma","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"R164-20260405","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"Ezh2 phosphorylation by jak3 mediates a switch to noncanonical function in natural killer\/t-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"R165-20260405","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of myc-mediated mir-29 by hdac3 and ezh2 as a therapeutic target of histone modification in aggressive b-cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"R166-20260405","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/s41401-023-01097-4","article-title":"Dysregulation of iron homeostasis by tfr-1 renders ezh2 wild type diffuse large b-cell lymphoma resistance to ezh2 inhibition","volume":"44","author":"Yu","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"R167-20260405","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"Ezh2 inhibition enhances t cell immunotherapies by inducing lymphoma immunogenicity and improving t cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"R168-20260405","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of mhc deficiency identifies ezh2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"key":"R169-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1578665","article-title":"Dual targeting of ezh2 and pd-l1 in burkitt\u2019s lymphoma enhances immune activation and induces apoptotic pathway","volume":"16","author":"Jeong","year":"2025","journal-title":"Front Immunol"},{"key":"R170-20260405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase ii study of anti-pd-1 camrelizumab plus decitabine in relapsed\/refractory hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R171-20260405","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","article-title":"Selective inhibitors of nuclear export (sine)--a novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J Hematol Oncol"},{"key":"R172-20260405","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","article-title":"The nuclear export protein xpo1 \u2014 from biology to targeted therapy","volume":"18","author":"Azmi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R173-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/biom13010111","article-title":"Nuclear export in non-hodgkin lymphoma and implications for targeted xpo1 inhibitors","volume":"13","author":"Trkulja","year":"2023","journal-title":"Biomolecules"},{"key":"R174-20260405","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1186\/s12885-015-1790-z","article-title":"Deciphering mechanisms of drug sensitivity and resistance to selective inhibitor of nuclear export (sine) compounds","volume":"15","author":"Crochiere","year":"2015","journal-title":"BMC Cancer"},{"key":"R175-20260405","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40262-021-01016-y","article-title":"Pharmacokinetics of selinexor: The first-in-class selective inhibitor of nuclear export","volume":"60","author":"Bader","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R176-20260405","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large b-cell lymphoma (sadal): A single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"R177-20260405","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-021-01122-1","article-title":"Survival among patients with relapsed\/refractory diffuse large b cell lymphoma treated with single-agent selinexor in the sadal study","volume":"14","author":"Maerevoet","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R178-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152672","article-title":"Phase ib study of oral selinexor in combination with rituximab and platinum chemotherapy in patients with relapsed\/refractory b-cell lymphoma-final analysis","volume":"16","author":"Maerevoet","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R179-20260405","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13045-020-00982-3","article-title":"Xpo1 expression worsens the prognosis of unfavorable dlbcl that can be effectively targeted by selinexor in the absence of mutant p53","volume":"13","author":"Deng","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R180-20260405","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/oncolo\/oyad241","article-title":"Selinexor with anti-pd-1 antibody as a potentially effective regimen for patients with natural killer\/t-cell lymphoma failing prior l-asparaginase and pd-1 blockade","volume":"29","author":"Tao","year":"2024","journal-title":"Oncologist"},{"key":"R181-20260405","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00277-025-06271-8","article-title":"Efficacy and mechanism of the xpo1 inhibitor selinexor combined with decitabine in t-cell lymphoblastic lymphoma","volume":"104","author":"Meng","year":"2025","journal-title":"Ann Hematol"},{"key":"R182-20260405","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","article-title":"Integrated safety profile of selinexor in multiple myeloma: Experience from 437 patients enrolled in clinical trials","volume":"34","author":"Gavriatopoulou","year":"2020","journal-title":"Leukemia"},{"key":"R183-20260405","article-title":"The xpo1 inhibitor kpt-8602 ameliorates parkinson\u2019s disease by inhibiting the nf-\u03bab\/nlrp3 pathway","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"R184-20260405","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation xpo1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"R185-20260405","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428194.2020.1775210","article-title":"Selinexor for advanced hematologic malignancies","volume":"61","author":"Walker","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"R186-20260405","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/stat pathway: Mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R187-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (jak) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"key":"R188-20260405","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1097\/CM9.0000000000003152","article-title":"Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer\/t cell lymphoma","volume":"137","author":"Wang","year":"2024","journal-title":"Chin Med J"},{"key":"R189-20260405","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the jak\/stat pathway in t cell lymphoma pathogenesis: Implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"R190-20260405","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.blre.2015.06.002","article-title":"Deregulated jak\/stat signalling in lymphomagenesis, and its implications for the development of new targeted therapies","volume":"29","author":"Scott","year":"2015","journal-title":"Blood Reviews"},{"key":"R191-20260405","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of jak\/stat targeting in t-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"R192-20260405","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.annonc.2023.08.013","article-title":"Phase i dose escalation and expansion study of golidocitinib, a highly selective jak1 inhibitor, in relapsed or refractory peripheral t-cell lymphomas","volume":"34","author":"Song","year":"2023","journal-title":"Ann Oncol"},{"key":"R193-20260405","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood-2021-149675","article-title":"Ruxolitinib plus nivolumab in patients with r\/r hodgkin lymphoma after failure of check-point inhibitors: Preliminary report on safety and efficacy","volume":"138","author":"Bachanova","year":"2021","journal-title":"Blood"},{"key":"R194-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-023-01436-6","article-title":"Aberrant jak-stat signaling-mediated chromatin remodeling impairs the sensitivity of nk\/t-cell lymphoma to chidamide","volume":"15","author":"Chen","year":"2023","journal-title":"Clin Epigenetics"},{"key":"R195-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010019","article-title":"Stat3 activation and oncogenesis in lymphoma","volume":"12","author":"Zhu","year":"2019","journal-title":"Cancers"},{"key":"R196-20260405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12885-019-5295-z","article-title":"Overcoming acquired resistance to hsp90 inhibition by targeting jak-stat signalling in triple-negative breast cancer","volume":"19","author":"Mumin","year":"2019","journal-title":"BMC Cancer"},{"key":"R197-20260405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010783","article-title":"Jak3a573vandjak3m511imutations in peripheral t-cell lymphoma mediating resistance to anti-pd-1 therapy through the stat3\/pd-l1 pathway","volume":"13","author":"Lou","year":"2025","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"R198-20260405","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1182\/bloodadvances.2024015332","article-title":"Thyroid hormones contribute to jak\/stat pathway abnormal activation, promoting t-cell lymphoma dissemination","volume":"9","author":"Debernardi","year":"2025","journal-title":"Blood Adv"},{"key":"R199-20260405","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3324\/haematol.2022.281226","article-title":"Monomorphic epitheliotropic intestinal t-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome","volume":"108","author":"Veloza","year":"2023","journal-title":"Haematologica"},{"key":"R200-20260405","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2019004118","article-title":"Hepatosplenic t-cell lymphoma: A rare but challenging entity","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"},{"key":"R201-20260405","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1097\/CM9.0000000000003904","article-title":"The cgas-sting signaling pathway as a therapeutic target in human diseases","volume":"138","author":"Xiao","year":"2025","journal-title":"Chin Med J"},{"key":"R202-20260405","article-title":"Cgas-sting signaling pathway in intestinal homeostasis and diseases","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"R203-20260405","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","article-title":"The cgas\u2013sting pathway and cancer","volume":"3","author":"Samson","year":"2022","journal-title":"Nat Cancer"},{"key":"R204-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00916-z","article-title":"Cgas-sting, an important pathway in cancer immunotherapy","volume":"13","author":"Jiang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R205-20260405","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7150\/ijbs.84890","article-title":"The role of cgas-sting signalling in metabolic diseases: From signalling networks to targeted intervention","volume":"20","author":"Gong","year":"2024","journal-title":"Int J Biol Sci"},{"key":"R206-20260405","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.7150\/ijbs.85236","article-title":"Activation of sting by samhd1 deficiency promotes panoptosis and enhances efficacy of pd-l1 blockade in diffuse large b-cell lymphoma","volume":"19","author":"Cai","year":"2023","journal-title":"Int J Biol Sci"},{"key":"R207-20260405","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009212","article-title":"Bendamustine\u2013rituximab elicits dual tumoricidal and immunomodulatory responses via cgas\u2013sting activation in diffuse large b-cell lymphoma","volume":"12","author":"Xiao","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R208-20260405","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/s41375-025-02627-1","article-title":"Sulforaphane promotes natural killer cell-mediated anti-tumor immune responses partially via cgas-sting pathway in classical hodgkin lymphoma","volume":"39","author":"Xagoraris","year":"2025","journal-title":"Leukemia"},{"key":"R209-20260405","article-title":"Targeting the cgas-sting pathway inhibits peripheral t-cell lymphoma progression and enhances the chemotherapeutic efficacy","volume":"11","author":"Lu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"R210-20260405","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116237","article-title":"Ddx3x mutation and epstein-barr virus cooperate to induce r-loop-dependent oncogenesis","volume":"44","author":"Cai","year":"2025","journal-title":"Cell Rep"},{"key":"R211-20260405","article-title":"Cgas\u2013sting, an important signaling pathway in diseases and their therapy","volume":"5","author":"Li","year":"2024","journal-title":"MedComm"},{"key":"R212-20260405","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41581-022-00589-6","article-title":"Role of the cgas\u2013sting pathway in systemic and organ-specific diseases","volume":"18","author":"Skopelja-Gardner","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"R213-20260405","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2024.04.004","article-title":"Putting the sting back into bh3-mimetic drugs for tp53-mutant blood cancers","volume":"42","author":"Diepstraten","year":"2024","journal-title":"Cancer Cell"},{"key":"R214-20260405","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1021\/acs.accounts.3c00394","article-title":"Engineering and delivery of cgas-sting immunomodulators for the immunotherapy of cancer and autoimmune diseases","volume":"56","author":"Zhou","year":"2023","journal-title":"Acc Chem Res"},{"key":"R215-20260405","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"key":"R216-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051276","article-title":"Targeted agents in the treatment of indolent b-cell non-hodgkin lymphomas","volume":"14","author":"Minson","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R217-20260405","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.2147\/CMAR.S267258","article-title":"Chemotherapy-free management of follicular and marginal zone lymphoma","volume":"13","author":"Ollila","year":"2021","journal-title":"Cancer Manag Res"},{"key":"R218-20260405","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"R219-20260405","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.14669","article-title":"Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma","volume":"181","author":"Srour","year":"2017","journal-title":"Br J Haematol"},{"key":"R220-20260405","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S2666-7568(22)00123-4","article-title":"Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large b-cell lymphoma: A phase 2, single-arm study","volume":"3","author":"Xu","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"R221-20260405","article-title":"A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large b-cell lymphoma","author":"Xu","year":"2025","journal-title":"Blood"},{"key":"R222-20260405","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1097\/CM9.0000000000002940","article-title":"Favorable outcomes of front-line risk-adapted therapy in young patients with diffuse large b-cell lymphoma with clinically or biologically high-risk features","volume":"137","author":"Zou","year":"2024","journal-title":"Chin Med J"},{"key":"R223-20260405","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hon.2781","article-title":"Precision medicine in follicular lymphoma: Focus on predictive biomarkers","volume":"38","author":"Sorigue","year":"2020","journal-title":"Hematol Oncol"},{"key":"R224-20260405","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"D\u00f6hner","year":"2018","journal-title":"Leukemia"},{"key":"R225-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1068662","article-title":"Emerging predictive biomarkers for novel therapeutics in peripheral t-cell and natural killer\/t-cell lymphoma","volume":"14","author":"Yap","year":"2023","journal-title":"Front Immunol"},{"key":"R226-20260405","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","article-title":"Janus kinase 3-activating mutations identified in natural killer\/t-cell lymphoma","volume":"2","author":"Koo","year":"2012","journal-title":"Cancer Discov"},{"key":"R227-20260405","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/jcmm.17667","article-title":"Protein biomarkers for response to xpo1 inhibition in haematologic malignancies","volume":"27","author":"Totiger","year":"2023","journal-title":"J Cell Mol Med"},{"key":"R228-20260405","article-title":"Multimodal profiling identifies cd4+cxcr5+pd-1- tfh cells as prognostic and predictive biomarkers in diffuse large b-cell lymphoma","author":"Yu","year":"2025","journal-title":"Chin Med J"},{"key":"R229-20260405","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large b-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"R230-20260405","article-title":"Genomic and transcriptomic profiling of peripheral t cell lymphoma reveals distinct molecular and microenvironment subtypes","volume":"5","author":"Huang","year":"2024","journal-title":"Cell Rep Med"},{"key":"R231-20260405","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large b cell lymphoma: The randomized guidance-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"R232-20260405","article-title":"Targeted agents plus chop compared with chop as the first-line treatment for newly diagnosed patients with peripheral t-cell lymphoma (guidance-03): An open-label, multicentre phase 2 clinical trial","volume":"50","author":"Cai","year":"2024","journal-title":"Lancet Reg Health West Pac"},{"key":"R233-20260405","article-title":"Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large b cell lymphoma: A phase 2 investigator-initiated nonrandomized clinical trial (guidance-06)","volume":"10","author":"Shen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R234-20260405","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hon.2933","article-title":"The resistance mechanisms and treatment strategies of btk inhibitors in b-cell lymphoma","volume":"39","author":"Wang","year":"2021","journal-title":"Hematol Oncol"},{"key":"R235-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.948513","article-title":"Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies","volume":"12","author":"Deshpande","year":"2022","journal-title":"Front Oncol"},{"key":"R236-20260405","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abg5216","article-title":"Kinase-deficient btk mutants confer ibrutinib resistance through activation of the kinase hck","volume":"15","author":"Dhami","year":"2022","journal-title":"Sci Signal"},{"key":"R237-20260405","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/leu.2014.263","article-title":"Functional characterization of btk(c481s) mutation that confers ibrutinib resistance: Exploration of alternative kinase inhibitors","volume":"29","author":"Cheng","year":"2015","journal-title":"Leukemia"},{"key":"R238-20260405","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to btk inhibition by ibrutinib can be overcome by preventing foxo3a nuclear export and pi3k\/akt activation in b-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis"},{"key":"R239-20260405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s12307-019-00232-2","article-title":"Tumor-infiltrating immunosuppressive cells in cancer-cell plasticity, tumor progression and therapy response","volume":"12","author":"Lorenzo-Sanz","year":"2019","journal-title":"Cancer Microenviron"},{"key":"R240-20260405","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.2023021000","article-title":"Cell cross talk within the lymphoma tumor microenvironment: Follicular lymphoma as a paradigm","volume":"143","author":"Laurent","year":"2024","journal-title":"Blood"},{"key":"R241-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055004","article-title":"Venetoclax-resistant t-all cells display distinct cancer stem cell signatures and enrichment of cytokine signaling","volume":"24","author":"Shah","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R242-20260405","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/CM9.0000000000002919","article-title":"Immune cells in the b-cell lymphoma microenvironment: From basic research to clinical applications","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin Med J"},{"key":"R243-20260405","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1097\/CM9.0000000000003690","article-title":"Decoding the immune microenvironment of secondary chronic myelomonocytic leukemia due to diffuse large b-cell lymphoma with cd19 car-t failure by single-cell rna-sequencing","volume":"138","author":"Li","year":"2025","journal-title":"Chin Med J"},{"key":"R244-20260405","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","article-title":"Targeted protein degradation by protacs","volume":"174","author":"Neklesa","year":"2017","journal-title":"Pharmacol Ther"},{"key":"R245-20260405","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the c481s ibrutinib-resistance mutation in bruton\u2019s tyrosine kinase using protac-mediated degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"R246-20260405","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13045-022-01386-1","article-title":"Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia","volume":"15","author":"Muhowski","year":"2022","journal-title":"J Hematol Oncol"},{"key":"R247-20260405","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamasurg.2023.5394","article-title":"Applications of liquid biopsy for surgical patients with cancer: A review","volume":"159","author":"Mahuron","year":"2024","journal-title":"JAMA Surg"},{"key":"R248-20260405","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8618","article-title":"Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges","volume":"8","author":"Sanz-Garcia","year":"2022","journal-title":"Sci Adv"},{"key":"R249-20260405","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1002\/cam4.5615","article-title":"Decitabine combined with rdhap regimen in relapsed\/refractory diffuse large b cell lymphoma","volume":"12","author":"Kong","year":"2023","journal-title":"Cancer Med"},{"key":"R250-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.969660","article-title":"Decitabine-primed tandem cd19\/cd22 car-t therapy in relapsed\/refractory diffuse large b-cell lymphoma patients","volume":"13","author":"Qu","year":"2022","journal-title":"Front Immunol"},{"key":"R251-20260405","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","article-title":"Hdac inhibitors overcome immunotherapy resistance in b-cell lymphoma","volume":"11","author":"Wang","year":"2020","journal-title":"Protein Cell"},{"key":"R252-20260405","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bjh.13318","article-title":"Entinostat, a novel histone deacetylase inhibitor is active in b-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents","volume":"169","author":"Frys","year":"2015","journal-title":"Br J Haematol"},{"key":"R253-20260405","doi-asserted-by":"crossref","DOI":"10.1126\/science.ade8520","article-title":"Jak inhibition enhances checkpoint blockade immunotherapy in patients with hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"R254-20260405","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40164-022-00356-0","article-title":"New insights into epigenetic regulation of resistance to pd-1\/pd-l1 blockade cancer immunotherapy: Mechanisms and therapeutic opportunities","volume":"11","author":"Dai","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"R255-20260405","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231208608","article-title":"The therapeutic synergy of selinexor and venetoclax in mantle cell lymphoma through induction of DNA damage and perturbation of the DNA damage response","volume":"22","author":"Yuan","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"R256-20260405","article-title":"Simultaneous targeting of xpo1 and bcl2 as an effective treatment strategy for double-hit lymphoma","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"R257-20260405","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1631\/jzus.B2200016","article-title":"Hdac inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large b-cell lymphoma via down-regulation of myc, bcl2, and tp53 expression","volume":"23","author":"Luo","year":"2022","journal-title":"J Zhejiang Univ Sci B"},{"key":"R258-20260405","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919830826","article-title":"Combined targeted therapy and immunotherapy in melanoma: A review of the impact on the tumor microenvironment and outcomes of early clinical trials","volume":"11","author":"Pelster","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"R259-20260405","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1097\/CM9.0000000000003085","article-title":"Chinese expert consensus on integrated case management by a multidisciplinary team in car-t cell therapy for lymphoma","volume":"138","author":"Tu","year":"2025","journal-title":"Chin Med J"},{"key":"R260-20260405","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911526","article-title":"Therapeutic advances in immunotherapies for hematological malignancies","volume":"23","author":"Nogami","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R261-20260405","article-title":"Long-term outcomes of cnct19 chimeric antigen receptor t-cell therapy in relapsed or refractory aggressive b-cell lymphoma","author":"Liu","year":"2025","journal-title":"Chin Med J"},{"key":"R262-20260405","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13696998.2021.2007704","article-title":"Economic evaluation of polatuzumab-bendamustine-rituximab vs. Tafasitamab-lenalidomide in transplant-ineligible r\/r dlbcl","volume":"24","author":"Calamia","year":"2021","journal-title":"J Med Econ"},{"key":"R263-20260405","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1397613","article-title":"Obstacles to global implementation of car t cell therapy in myeloma and lymphoma","volume":"14","author":"Medina-Olivares","year":"2024","journal-title":"Front Oncol"},{"key":"R264-20260405","doi-asserted-by":"crossref","first-page":"71548","DOI":"10.18632\/oncotarget.17742","article-title":"A global comparison of the cost of patented cancer drugs in relation to global differences in wealth","volume":"8","author":"Goldstein","year":"2017","journal-title":"Oncotarget"},{"key":"R265-20260405","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/GO.20.00012","article-title":"Comparison of access to novel drugs for lymphoma and chronic lymphocytic leukemia between india and the united states","author":"Sathyanarayanan","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"R266-20260405","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01124-5","article-title":"Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma","volume":"14","author":"Bai","year":"2024","journal-title":"Blood Cancer J"},{"key":"R267-20260405","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/s41375-025-02563-0","article-title":"Discrete genetic subtypes and tumor microenvironment signatures correlate with peripheral t-cell lymphoma outcomes","volume":"39","author":"Suehara","year":"2025","journal-title":"Leukemia"},{"key":"R268-20260405","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41598-018-38179-x","article-title":"Enabling precision medicine by unravelling disease pathophysiology: Quantifying signal transduction pathway activity across cell and tissue types","volume":"9","author":"van de Stolpe","year":"2019","journal-title":"Sci Rep"},{"key":"R269-20260405","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semcancer.2023.06.004","article-title":"Artificial intelligence in digital pathology of cutaneous lymphomas: A review of the current state and future perspectives","volume":"94","author":"Doeleman","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"R270-20260405","article-title":"Artificial intelligence for diagnosis and prognosis prediction of natural killer\/t cell lymphoma using magnetic resonance imaging","volume":"5","author":"Zhang","year":"2024","journal-title":"Cell Rep Med"},{"key":"R271-20260405","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.semnuclmed.2025.02.007","article-title":"The role of ai in lymphoma: An update","volume":"55","author":"Cairns","year":"2025","journal-title":"Semin Nucl Med"},{"key":"R272-20260405","article-title":"Integrating multi-omics features enables non-invasive early diagnosis and treatment response prediction of diffuse large b-cell lymphoma","volume":"15","author":"Zhang","year":"2025","journal-title":"Clin Transl Med"},{"key":"R273-20260405","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-025-02321-x","article-title":"Emerging artificial intelligence-driven precision therapies in tumor drug resistance: Recent advances, opportunities, and challenges","volume":"24","author":"Mao","year":"2025","journal-title":"Mol Cancer"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T04:00:57Z","timestamp":1775361657000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000004017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":273,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004017","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"2025-09-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}